Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib in BRAF non-V600 Melanoma
NCT02296112Phase 2Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Jan 2015
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trametinib in melanoma, sponsored by Vanderbilt-Ingram Cancer Center. Started Jan 2015; status: completed.
02
Drugs
trametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02296112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02296112.